UnknownPhase 4

H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection

South Korea232 participantsStarted 2008-09

Plain-language summary

This study will evaluate the effect of Helicobacter pylori eradication therapy on the healing of iatrogenic gastric ulcer caused by endoscopic mucosal resection of gastric neoplastic lesions and is a multicenter, randomized, double blind, and placebo controlled trial.

Who can participate

Age range30 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 30 - 75 years old * Early gastric cancer (\< 3 cm in size, mucosa confined, differentiated type) or gastric adenoma (\< 3 cm in size) * Helicobacter pylori positive Exclusion Criteria: * Medication of anti-secretory drugs (proton pump inhibitors, H2-receptor antagonists, antacid, bismuth compound) * History of Helicobacter pylori eradication * History of gastric surgery or other cancers * Major comorbidities * Medication of ASA, NSAIDS, steroids, anti-coagulants

What they're measuring

ulcer healing rate by endoscopic assessment

Timeframe: 8 weeks

Trial details

NCT IDNCT00926809

SponsorKorean College of Helicobacter and Upper Gastrointestinal Research

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-09

Contact for this trial

Ho June Song, Ph.D

82-2-3010-3916 hojunesong@yahoo.co.kr

View on ClinicalTrials.gov More Ulcer trials